Biogen Beats Second-Quarter Expectations

Shares of Biogen (NASDAQ: BIIB) hardly moved following the release of second-quarter earnings results that beat Wall Street's expectations on the top and bottom lines.  

Revenue rose 1.7% year over year to $3.7 billion, exceeding the average analyst estimate by $240 million. Adjusted earnings rose 12% to $10.26 per share, $2.25 per share higher than expected.

Image source: Getty Images.

Continue reading

Source Fool.com